分子POCT: 瞬間診断の新時代を開拓する

In the rapidly evolving landscape of medical technology, Molecular Point-of-Care Testing (POCT) is emerging as a shining star in the field of medical diagnostics. By integrating nucleic acid extraction, amplification, and detection into a single, closed, and portable device, Molecular POCT has simplified the diagnostic process while effectively minimizing the risk of sample contamination. This innovative approach promises faster and more accurate diagnostic capabilities.

Technical Principles: A Perfect Blend of Miniaturization and High Efficiency

The core technologies of Molecular POCT include real-time fluorescent PCR (qPCR) and Loop-Mediated Isothermal Amplification (LAMP). qPCR, known for its high sensitivity and specificity, is widely used in infectious disease detection, such as screening for COVID-19, influenza, and tuberculosis. LAMP, on the other hand, requires no complex thermal cycling equipment, making it a fast and suitable option for primary healthcare settings. さらに, the latest research has combined microfluidic chips with CRISPR/Cas12a technology, enabling physical separation of the isothermal amplification and detection processes, thereby further enhancing sensitivity and accuracy.

Application Scenarios: Comprehensive Coverage from Hospitals to Homes

The applications of Molecular POCT are incredibly diverse, spanning emergency departments in hospitals, primary healthcare units, and home health monitoring. In ICU wards, Molecular POCT can rapidly provide diagnostic results, buying valuable time for critically ill patients. In outpatient and emergency laboratories, its modular design and on-demand testing capabilities meet the needs of patients requiring quick diagnostics. さらに, Molecular POCT is widely used in community healthcare, health check-up centers, customs quarantine, and food safety testing.

Market Trends: High-Speed Growth Driven by Technological Innovation

In recent years, the Molecular POCT market has experienced rapid growth. In 2023, the global sales of POCT molecular diagnostic technologies reached $5.683 billion, with projections indicating it will reach $10.128 billion by 2030. In China, the market is also expanding swiftly, with a 2023 market size of $266 million, expected to grow to $711 million by 2030. As technology continues to advance and application scenarios expand, Molecular POCT is becoming an indispensable part of the medical diagnostics landscape.

Future Outlook: Intelligent POCT Leading the Way in Healthcare

With the integration of emerging technologies such as artificial intelligence and the Internet of Things, Molecular POCT is poised to become even smarter and more precise. These devices will not only enable remote operation and data sharing but also provide support for medical decision-making through cloud-based platforms. From epidemic control to chronic disease management, from community healthcare to home health monitoring, the future of Molecular POCT is bright, offering endless possibilities for human health.

分子POCT, as a leading-edge representative of instantaneous diagnostic technology, is transforming the future of medical diagnostics with its efficiency, convenience, and accuracy.

サプライヤー

上海霊軍生物技術有限公司, 株式会社に設立されました 2016 生体磁性材料と核酸抽出試薬の専門メーカーです.

核酸抽出・精製の経験が豊富です。, タンパク質の精製, 細胞分離, 化学発光, その他の技術分野.

当社の製品はさまざまな分野で広く使用されています, 医療検査など, 遺伝子検査, 大学の研究, 遺伝子育種, 等々. 製品のご提供だけでなくOEMも承ります, ODM, その他のニーズ. 関連するニーズがある場合, お気軽にお問い合わせください .